A PKCα-specific antisense oligonucleotide, aprinocarsen (ISIS3521/LY900003; a 20-base antisense oligonucleotide), has been applied in Phase II or/and III clinical trials in patients with recurrent high-grade astrocytomas [193], advanced NSCLC [194,195], advanced ovarian carcinoma [196], hormone-refractory prostate cancer [197], metastatic colorectal cancer [198], and previously treated low-grade non-Hodgkin’s lymphoma (NHL) [199]. Here, PRKCA is linked to non-Hodgkin lymphoma.